RBS-001 (aflibercept biosimilar)
/ Rophibio
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
April 07, 2025
A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degeneration
(clinicaltrials.gov)
- P3 | N=434 | Not yet recruiting | Sponsor: Rophibio, Inc. | Initiation date: Jan 2025 ➔ Jul 2025
Trial initiation date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration
December 05, 2024
A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects with Neovascular Age-Related Macular Degeneration
(clinicaltrials.gov)
- P3 | N=434 | Not yet recruiting | Sponsor: Rophibio, Inc. | Initiation date: Sep 2024 ➔ Jan 2025
Trial initiation date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration
1 to 2
Of
2
Go to page
1